B
Bull
Bull · 25%SONN
$21.92
Scenario price
$1.260
-0.748 (-59.35%)At close
Loading chart…
- High
- 3.230
- Open
- 3.160
- VWAP
- 1.92
- Vol
- 10.46M
- Mkt Cap
- 2.95M
- Low
- 1.260
- Amount
- 20.04M
- EV/EBITDA, TTM
- 0.00
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
Valuation Metrics
The current forward P/E ratio for Sonnet Biotherapeutics Holdings Inc (SONN) is -0.36, compared to its 5-year average forward P/E of -0.65.
Alphio AI Price Scenarios for SONN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
8.512-02NewsfilterHyperliquid Completes Merger with Sonnet, Stock to Trade on Nasdaq
- 8.512-02Newsfilter
Sonnet BioTherapeutics Shareholders Approve Merger with Hyperliquid Strategies Inc.
8.512-02GlobenewswireSonnet BioTherapeutics Secures Shareholder Approval for Merger with Hyperliquid Strategies
2.012-01NASDAQ.COMBiotech Stocks Surge in After-Hours Trading with Gains from BioAtla, Entero, and Sonnet
- 1.009-19Newsfilter
Sonnet to Showcase at the MedInvest Biotech & Pharma Conference
SONN FAQ — answered by Alphio AI
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.